Quantum BioPharma ( ) - 株価, ニュースと分析Nasdaq:QNTM

QNTM 株式概要

クオンタム・バイオファーマは、神経変性疾患、炎症性疾患、代謝性疾患、アルコール乱用性疾患などの難治性疾患の治療薬として、さまざまな開発段階にある医薬品候補を研究開発するバイオ医薬品企業である。詳細

QNTM ファンダメンタル分析
スノーフレーク・スコア
評価	2/6
将来の成長	0/6
過去の実績	0/6
財務の健全性	4/6
配当金	0/6

報酬

過去5年間の収益は年間19.1%増加しました。

リスク分析

過去1年間で株主の希薄化は大幅に進んだ

収益が 100 万ドル未満 ( $0 )

キャッシュランウェイが1年未満である

過去3か月間の株価の変動は非常に激しい

+1 さらなるリスク

Quantum BioPharma Ltd. 競合他社

Kiora Pharmaceuticals

NasdaqCM:KPRX

US$10.1m

Jaguar Health

NasdaqCM:JAGX

US$9.6m

Aytu BioPharma

NasdaqCM:AYTU

US$10.0m

Eyenovia

NasdaqCM:EYEN

US$9.3m

価格と性能

の歴代最高値、変動、値下がりまとめQuantum BioPharma
過去の株価
現在の株価	CA$5.22
52週高値	CA$89.70
52週安値	CA$3.50
ベータ	0.76
11ヶ月の変化	-7.84%
3ヶ月変化	18.64%
1年変化	-93.63%
33年間の変化	-93.77%
5年間の変化	-98.30%
IPOからの変化	-99.52%

Recent updates

株主還元

	QNTM	US Pharmaceuticals	US 市場
7D	6.1%	2.8%	2.2%
1Y	-93.6%	11.8%	32.6%

業界別リターン: QNTM過去 1 年間で11.8 % の収益を上げたUS Pharmaceuticals業界を下回りました。

リターン対市場: QNTMは、過去 1 年間で32.6 % のリターンを上げたUS市場を下回りました。

価格変動

Is QNTM's price volatile compared to industry and market?
QNTM volatility
QNTM Average Weekly Movement	17.4%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.8%
10% least volatile stocks in US Market	3.1%

安定した株価: QNTMの株価は過去 3 か月間にわたって変動しています。

時間の経過による変動: QNTMの週次ボラティリティは過去 1 年間で23%から17%に減少しましたが、依然としてUS株の 75% よりも高くなっています。

会社概要

設立	従業員	CEO（最高経営責任者	ウェブサイト
n/a	17	Zeeshan Saeed	www.fsdpharma.com

クオンタム・バイオファーマ社はバイオ医薬品会社であり、神経変性疾患、炎症性疾患、代謝性疾患、アルコール乱用性疾患などの難治性疾患の治療薬として、さまざまな開発段階にある医薬品候補を含む資産とバイオテクノロジー・ソリューションのポートフォリオを研究開発している。同社はバイオ医薬品と戦略的投資の2つのセグメントで事業を展開している。リード化合物はLucid-MSで、多発性硬化症の基礎メカニズムであるミエリン分解を予防・逆転させる特許取得済みの新規化学物質であり、前臨床モデルで第2相臨床試験中である。同社はまた、病院やその他の医療現場での応用を目指し、アルコール誤用治療薬も開発している。さらに、住宅用不動産を担保とする融資からなる戦略的投資ポートフォリオを維持している。同社は以前はFSD Pharma Inc.として知られていたが、2024年8月にQuantum BioPharma Ltd.に社名を変更した。本社はカナダのトロント。

Quantum BioPharma Ltd. 基礎のまとめ

Quantum BioPharma の収益と売上を時価総額と比較するとどうか。
QNTM 基礎統計学
時価総額	US$10.50m
収益（TTM）	-US$10.24m
売上高(TTM)	n/a

0.0x

P/Sレシオ

-1.0x

PER（株価収益率

QNTM は割高か？

公正価値と評価分析を参照

収益と収入

最新の決算報告書（TTM）に基づく主な収益性統計
QNTM 損益計算書（TTM）
収益	US$0
売上原価	US$0
売上総利益	US$0
その他の費用	US$10.24m
収益	-US$10.24m

直近の収益報告

Sep 30, 2024

次回決算日

該当なし

一株当たり利益（EPS）	-5.33
グロス・マージン	0.00%
純利益率	0.00%
有利子負債／自己資本比率	2.0%

QNTM の長期的なパフォーマンスは？

過去の実績と比較を見る

QNTM 株式概要

報酬

リスク分析

Quantum BioPharma Ltd. 競合他社

NasdaqCM:KPRX

US$10.1m

NasdaqCM:JAGX

US$9.6m

NasdaqCM:AYTU

US$10.0m

NasdaqCM:EYEN

US$9.3m

価格と性能

最新ニュース

New major risk - Financial position

Quantum BioPharma Regains Nasdaq Listing Compliance

Quantum Biopharma Announces Celly Nutrition Launches Unbuzzd(Tm) Grab-And-Go Stick Packs on Amazon.Com So You Can "Own Now and What’S Next"

Quantum BioPharma Ltd. Announces Executive Appointments

New major risk - Financial position

FSD Pharma Announces Share Consolidation, Part of the Company's Plan to Regain Compliance with Nasdaq Minimum Bid Price Requirement

Recent updates

New major risk - Financial position

Quantum BioPharma Regains Nasdaq Listing Compliance

Quantum Biopharma Announces Celly Nutrition Launches Unbuzzd(Tm) Grab-And-Go Stick Packs on Amazon.Com So You Can "Own Now and What’S Next"

Quantum BioPharma Ltd. Announces Executive Appointments

New major risk - Financial position

FSD Pharma Announces Share Consolidation, Part of the Company's Plan to Regain Compliance with Nasdaq Minimum Bid Price Requirement

New major risk - Shareholder dilution

FSD Pharma Inc. Receives Ethics Committee Approval for a Phase-1 Multiple Ascending Doses Clinical Trial for Lucid-21-302 (Lucid-MS) in Australia

New major risk - Market cap size

FSD Pharma Receives Institutional Review Board Approval to Study the Safety and Efficacy of Unbuzzd in Acute Alcohol Intoxication

New major risk - Financial position

FSD Pharma Inc. Submits A Phase-1 Multiple Ascending Doses Clinical Trial Application for Lucid-21-302 (Lucid-MS) for Ethics Committee Review in Australia

New minor risk - Shareholder dilution

FSD Pharma Inc. Submits A Phase-1B Clinical Trial Application for Ethics Committee for Its Proprietary Beverage Unbuzzd

FSD Pharma Inc. Presents Positive Results on First-In-Human Phase-1 Study of Lucid-21-302 (Lucid-Ms) At Americas Committee for Treatment and Research in Multiple Sclerosis (Actrims) 2024 Forum

FSD Pharma Inc. has filed a Follow-on Equity Offering in the amount of $11.154232 million.

FSD Pharma Inc. Announces Board Changes

FSD Pharma Inc. Provides an Update Regarding Its Litigation with GBB Drink Lab, Inc

GBB Maintains Strong Position in Its Ongoing Lawsuit with FSD Pharma After Court Refuses to Dismiss Case

FSD Pharma Inc. announced that it has received CAD 0.000046 million in funding

FSD Pharma Inc. announced that it has received CAD 0.000046 million in funding

FSD Pharma Inc. announced that it expects to receive CAD 0.000046 million in funding

New major risk - Financial position

FSD Pharma Inc. announced that it expects to receive CAD 0.000046 million in funding

FSD Pharma Inc. Announces Change of CEO

FSD Pharma Inc. Announces the Ontario Superior Court of Justice Has Dismissed the Motion to Set Aside the Arbitration Award to FSD Pharma Filed by Raza Bokhari

FSD Pharma Announces Interim Results from First-In-Human Clinical Trial of Lucid-MS (Lucid-21-302) for Multiple Sclerosis

FSD Pharma to Present Its Phase 1 Data on Lucid-MS At MSMilan 2023

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

FSD Pharma Inc. Announces CEO Changes

Raza Bokhari Files Two Additional Claims Against the FSD Pharma Seeking Relief and Monetary Damages Exceeding $30.2 Million

FSD Pharma Inc. Announces Board Changes

Founder recently bought US$328k worth of stock

FSD Pharma Regains Compliance with NASDAQ Continued Listing Requirements

FSD Pharma Inc. Receives Regulatory Clearance for its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug Candidate

FSD Pharma Inc. Announces Recruiting Is Underway for the Company's Phase 2 Clinical Trial of Fsd201 for the Treatment of Chronic Pain

FSD Pharma Inc. Announces Submission of Its Clinical Trial Application for Planned Phase-1 Trial for Lucid-MS

FSD Pharma Inc. Submits Its Phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigation

FSD Pharma Inc. Announces Committee Appointments

FSD Pharma Announces Changes to the Board of Directors

Less than half of directors are independent

FSD Pharma Inc. Announces Arbitrator Dismisses Claims by Former CEO, Dr. Raza Bokhari

FSD Pharma Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

FSD Pharma receives Nasdaq minimum bid price deficiency notification

FSD Pharma Inc. Receives “Study May Proceed” Letter for the Investigational New Drug Application from the U.S. Food and Drug Administration (“FDA”) and “Notice of Authorization” from Health Canada for its Phase 2 Clinical Trial of Fsd201

FSD Pharma gets clearance to start phase 2 trial of FSD201 in US, Canada

FSD Pharma Inc. Elects Fernando Cugliari as Director

FSD Pharma Inc. Files Investigational New Drug Application with FDA and Health Canada for Phase-2 Trial of FSD-201 for an Inflammatory Disorder and Provides Corporate Updates

FSD Pharma Inc. Announces Dismissal of Derivative Complaint

FSD Pharma Inc., Annual General Meeting, Jun 23, 2022

High number of new and inexperienced directors

FSD Pharma Inc. Appoints David Allan and John Mcgraw to the Company's Advisory Board

FSD Pharma Inc. Announces Executive Appointments

An unknown buyer entered into an agreement to acquire Cobourg Facility in Cobourg, Ontario from FSD Pharma Inc. (CNSX:HUGE) for CAD 16.5 million.

Founder recently bought US$40k worth of stock

Founder recently bought US$112k worth of stock

FSD Pharma Unveils Videos Demonstrating Positive Effects of Lucid-MS in Treating Multiple Sclerosis in Pre-Clinical Models (Mouse Models)

FSD Pharma Inc. (CNSX:HUGE) entered into a definitive agreement to acquire Lucid Psycheceuticals Inc. for CAD 9.7 million.